Assessing consumer gains from a drug price control policy in the United States

Southern Economic Journal

Volumn 73, Issue 1, 2006, Pages 233-245

  Santerre, Rexford E ^a   Vernon, John A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747079913     PISSN: 00384038     EISSN: None     Source Type: Journal    
DOI: 10.2307/20111885     Document Type: Review

References (23)

1. Berndt, Ernst R., Zvi Griliches, and Joshua G. Rosett. 1993. Auditing the producer price index: Micro evidence from prescription pharmaceutical preparations. Journal of Business and Economic Statistics 11:251-64.
2. Board of Governors of the Federal Reserve System. Interest rates. Available http://federalreserve.gov. Accessed July 2005.
3. Bureau of Economic Analysis (BEA). Current dollar and "real" GDP, 1929-2004. Available http://www.bea.gov. Accessed July 2005.
4. Bureau of Labor Statistics (BLS). Public data query. Available http://www.bls.gov. Accessed July 2005.
5. Centers for Medicare and Medicaid Services (CMS). National health expenditures, 1960-2003. Available http://www.cms.gov. Accessed July 2005.
6. Coulson, N. Edward, and Bruce C. Stuart. 1995. Insurance choice and the demand for prescription drugs. Southern Economic Journal 61:1146-57.
7. Cutler, David, and Mark McClellan. 2001. Is technological change in medicine worth it? Health Affairs Sept/Oct, pp. 11-29.
8. Feldstein, Martin S. 1973. The welfare loss of excess of health insurance. Journal of Political Economy 81:251-80.
9. Giaccotto, Carmelo, Rexford E. Santerre, and John A. Vernon. 2005. Drug prices and R&D investment behavior in the pharmaceutical industry. Journal of Law and Economics 48:195-214.
10. Hausman, Jerry. 2003. Sources of bias and solutions to bias in the consumer price index. Journal of Economic Perspectives 17(1):23-44.
11. Kanavos P., J. Costa-i-Font, S. Merkur, and M. Gemmill. 2004. The economic impact of pharmaceutical parallel trade in European Union member states: A stakeholders analysis. London School of Economics and Political Science working paper.
12. Lichtenberg, Frank. 1996. Do (more and better) drugs keep people out of hospitals? American Economic Review 86:384-8.
13. Lichtenberg, Frank. 2000. The effect of pharmaceutical utilisation and innovation on hospitalisation and mortality. In Productivity, technology, and economic growth, edited by B. van Ark, S. K. Kuipers, and G. Kuper. New York: Kluwer Academic Publishers, pp. 317-44.
14. Lichtenberg, Frank. 2002. Sources of U.S. longevity increase, 1960-1997. National Bureau of Economic Research Working Paper 8755, Cambridge, MA.
15. Maddala, G. S. 1992. Introduction to econometrics. New York: Macmillan Publishing Company.
16. Manning, W. G., and M. S. Marquis. 1996. Health insurance: The tradeoff between risk pooling and moral hazard. Journal of Health Economics 15:609-39.
17. Miller, Richard D., Jr., and H. E. Frech III. 2002. The productivity of health care and pharmaceuticals: Quality of life, cause of death, and the role of obesity. Mimeo. Santa Barbara, CA: University of California at Santa Barbara.
18. Murphy, Kevin, and Robert Topel. 2003. The economic value of medical research. In Measuring the gains from medical research, edited by Kevin M. Murphy and Robert H. Topel. Chicago, IL: The University of Chicago Press, pp. 41-73.
19. Santerre, Rexford E., and Stephen P. Neun. 2004. Health economics: Theories, insights, and industry studies. Mason, OH: Thomson Learning.
20. Santerre, Rexford E., John A. Vernon, and Carmelo Giaccotto. 2006. The impact of indirect government controls on U.S. drug prices and R&D. Cato Journal 26:143-58.
21. Scherer, F. M. 2004. The pharmaceutical industry - Prices and progress. The New England Journal of Medicine 351:927-32. U.S. Food and Drag Administration (PDA). Available http://www.fda.gov.
22. Vernon, John A. 2004. New evidence on drug price controls. Regulation 27(3):13-5.
23. Vernon, John A. 2005. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 14:1-17.